Title: Intravitreal anti-VEGF monotherapy in retinopathy of prematurity management, a case series of our first 10 eyes

Biography:

Rachid Chigara is ophthalmology trainee at Mustaphaan University hospital in Algiers. In his final year he has developed an interest in pediatric ophthalmology and currently works in the retinoblastoma unit at the same hospital, where conservative treatment of retinoblastoma is performed. After the Algerian society of ophthalmology’s 31st congress in 2016, whose main theme was ROP helped in retinopathy of prematurity screening and the treatment of certain cases using Anti-VEGF agents under the guidance of the head of the ophthalmology department.

Abstract

The purpose is to study the structural outcome of intravitreal injections of Ranibizumab in zone 2 stage 3 ROP. Premature infants born in CHU-Mustapha maternity hospital, who met our main screening criteria, (Infants born before 30weeks gestational age and/or weighing less than 1500g at birth and/or required any sort of ventilation assistance and oxygen therapy) were automatically sent for screening following discharge. All screenings were carried out using a Retcam 3, after pupil dilation, using both tropicamide and phenylephrine, on awake infants. stage 3 zone 2 ROP were treated in the operating theatre under strict aseptic conditions with a single injection of 0.20mg Ranibizumab. Follow up exams were also carried out using a Retcam 3, after pupil dilation, on awake infants, 48 hours, days 7, 14, 21, and 28 as well as every second week for 3 months and every month for six months or until completion of retinal vascularisation.